Tissuemed, which develops self-adhesive surgical sealant films, will enable BD to expand its global offerings for surgeons outside of the US
Becton, Dickinson and Company has acquired UK-based Tissuemed to add advanced surgical sealant solutions to its portfolio.
Based in Leeds, England, Tissuemed is involved in the development of self-adhesive surgical sealant films.
Tissuemed produces Tissuepatch, which is an advanced sealant technology that bonds to tissue to efficiently control internal bleeding or avoid leaks from surgical incisions.
Developed using TissueBond technology, the Tissuepatch portfolio consists of synthetic, self-adhesive, bioresorbable and biocompatible surgical sealant films.
With only 40μ thick, the resorbable Tissuepatch films are based on polymers that are commonly used in other surgical implants.
Designed to use in a range of surgical sealant applications, the Tissuepatch features a thin, flexible and transparent composition that makes it ready to use out of the package.
With its better design, Tissuepatch is said to enable strong adhesive and minimal swelling. It is also expected to help BD to leverage its reach and clinical expertise to continue to innovate within the sealant technology category.
BD surgery president Kevin Kelly said: “This advanced sealant serves as a strategic complement to the BD products used in the operating room today — providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions.
“Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”
The acquisition of Tissuemed will enable BD to expand its global offerings for surgeons outside of the US.